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Abstract 
The mammalian hypothalamus regulates key homeostatic and neuroendocrine 
functions ranging from circadian rhythm and energy-balance to growth and 
reproductive cycles via the hypothalamo-pituitary and hypothalamo-thyroid axes. In 
addition to its neurons, tanycytes are taking centre stage in the short and long term 
augmentation and integration of diverse hypothalamic functions, but the genetic 
regulators and mediators of their involvement are poorly understood. Exogenous 
interventions have implicated Fibroblast growth factor (FGF) signalling, but the focal 
point of FGF action and any role for putative endogenous players also remains 
elusive. We carried out a comprehensive high-resolution screen of FGF signalling 
pathway mediators and modifiers using a combination of in situ hybridization, 
immunolabelling and transgenic reporter mice, to map their spatial distribution in the 
adult hypothalamus. Our findings suggest that beta tanycytes are the likely focal 
point of exogenous and endogenous FGF action in the third ventricular wall, utilising 
FGF-receptors (FGFRs) -1 and -2 IIIc isoforms, but not FGFR3. Key IIIc-activating 
endogenous ligands include FGFs 1, 2, 9 and 18, which are expressed by a subset 
of ependymal and parenchymal cells. In the parenchymal compartment, FGFRs 1-3 
show divergent patterns, with FGFR1 predominant in neuronal nuclei and FGFR3 
expression being associated with glial cell function. Intracrine FGFs are also present, 
suggestive of multiple modes of FGF function. Our findings provide a testable 
framework for understanding the complex role of FGFs in regulating the metabolic 
endocrine and neurogenic functions of hypothalamus in vivo. 
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Introduction 
Growing evidence shows that in addition to hypothalamic neurons, tanycytes act as 
sensors, mediators and effectors for critical processes that underpin the homeostatic 
and neuroendocrine functions of hypothalamus, for example, sensing of metabolites 
and micronutrients and trafficking of peripheral and central signals such as Leptin 
and Gonadotropin-releasing hormone (GnRH) (1, 2). Moreover, a subset of 
tanycytes acts as bona fide neural stem/progenitor cells (NSPCs) in the postnatal 
and adult hypothalamus, capable of generating new energy balance-regulating 
neurons, and glia (3-5). Tanycytes are residual radial glial-like cells that occupy the 
floor and ventro-lateral walls of the third ventricle (3V). They have been subdivided 
into four main subtypes: Beta (β) 2, 1 and alpha (α) 2 and 1, according to a 
combination of projection trajectory, morphology, barrier properties, cilia 
arrangement and positioning within or outside marker domains within the 3V wall (1). 
Commonly, their apical surface is exposed to the cerebrospinal fluid (CSF) whilst 
their basal processes either contact the portal capillaries of the central (β2-tanycytes) 
and lateral (β1-tanycytes) median eminence, or terminate within the arcuate or 
ventromedial and dorsomedial nuclei (α-tanycytes), whose neurons are crucial for 
maintaining energy homeostasis and related food-seeking behaviour. 
Fibroblast growth factors (FGFs) are emerging as important regulators of tanycyte 
biology and hypothalamic neuronal function. The mammalian FGFs number 22 in 
total, 18 of which function as paracrine, endocrine or autocrine molecules by 
activating one of four types of FGF receptors (FGFRs 1-4) and the ensuing 
downstream intracellular signalling pathways: Ras-Raf-MAPK, PI3K-AKT and PLCγ 
(6, 7). The remaining FGFs (11-14) function intracellularly in a receptor-independent 
manner (8). FGFR signalling can modulate diverse aspects of cell behaviour in a 
cell-type specific manner. This is achieved partly through differential levels of 
signalling, established by intracellular negative feedback loop regulators such as 
Sproutys (Spry) and Map-kinase phosphatases (Mkp)(9). Tissue specificity of FGF 
action is governed by target cells’ expression of the so-called IIIb or IIIc alternatively-
spliced receptor isoforms which engage a mutually-exclusive set of FGFs (10). 
Moreover, co-factors such as sulphated proteoglycans (SPGs) and βKlotho 
molecules not only facilitate focal FGF/FGFR signalling but also determine the range 
of extracellular FGF diffusion. For example, peripherally generated FGFs -19 and -21 
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evade entrapment by Heparan Sulphate Proteoglycans (HSPG) to act as circulating 
hormones in the metabolic control of energy homeostasis, with potential clinical 
applications in the management of type 2 diabetes (11, 12). 
Exogenous FGF2 is a potent mitogen for hypothalamic ependymal and neural cells 
in vitro and in vivo (5, 13). Levels of FGF1 show a dramatic postprandial rise in the 
cerebrospinal fluid (CSF) (14, 15), whilst experimental elevation or attenuation of 
canonical FGF signalling, via peripheral or intracerebroventricular (ICV) application 
of FGF ligands, soluble FGFR fragments or neutralizing antibodies, can respectively 
induce hypo- and hyperphagia (16-19). Exogenous FGF1 also accelerates glucose 
clearance and induces sustained remission of diabetes symptoms in a diabetic 
mouse model (20). 
A full understanding of how exogenous FGFs function and/or whether endogenous 
FGFs have similar or unique roles, requires the identification and spatial distribution 
of the key players – ligands, receptors, receptor co-factors and signalling modifiers. 
To address this need, we carried out a detailed survey of FGF signalling pathway 
components in mediobasal hypothalamus, using RT-PCR screens, in conjunction 
with in situ hybridization, immunolabelling and analysis of transgenic reporter mice. 
Our investigations reveal intricate and restricted domains of FGF and FGFR receptor 
expression amongst tanycytes, in addition to distinct as well as overlapping patterns 
of receptor and ligand expression within the neighbouring energy balance regulating 
nuclei.  
 
Materials and Methods 
Animals 
Both male and female mice ranging in age from 30 to 80 days of age were used. All 
mice were bred and maintained on a mixed C57BL6/129Ola background, under a 
12-hour light/dark cycle, in accordance with local and national regulations and 
licenses governing experimental work with animals. Tissues from Fgf9-LacZ; Fgf18-
CreER and Etv4-GFP transgenic reporter mice were kindly provided by Professors 
David Ornitz and Saverio Bellusci, from previously described (21, 22) or recently 
generated strains. To detect Fgf18 expressing cells in the brain, mice carrying Fgf18-
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CreER::Rosa-tdTomato alleles were injected intraperitoneally with tamoxifen (300 
mg/ kg body weight) at P50, P51 and P52, before tissue harvest at P53.  
 
Tissue isolation and preparation 
Mice were culled by CO2 asphyxiation and brains were then dissected out and fixed 
for 4-16 hours overnight in 4% paraformaldehyde (PFA, pH 7.0) at 4°C. For fresh 
tissue and mRNA isolation, mice were culled by cervical dislocation and micro-
dissected hypothalami were flash frozen in cryotubes on dry ice and stored at -80 °C. 
To generate cryostat sections, the brains were washed with DEPC-treated PBS 
(DEPC-PBS) and cryo-protected in 30% w/v sucrose /DEPC-PBS solution for 48 
hours at 4 °C. Thereafter, they were placed in cryomoulds filled with optimal cutting 
temperature (OCT) compound, allowed to set on dry ice, and stored at -80 °C. 20 µm 
thick coronal sections containing the central part of median eminence (Bregma  -1.45 
to -1.94) were then generated using a freezing microtome (MicroM HM560) and 
thaw-mounted onto previously baked (180°C, overnight) Superfrost (ThermoFisher 
Scientific) slides, and stored at -80 °C until use. 
 
To generate vibratome sections, PFA-fixed brains were first dehydrated in ascending 
concentrations (30%, 50%, 70%, 90%; 1 hour per dilution) of ethanol, before being 
stored at 4 °C in absolute ethanol. Just before use, brains were rehydrated stepwise 
back to PBS and embedded in 3% w/v agar overnight. Coronal 60 µm-thick sections 
containing median eminence (Bregma -1.46 to -2.18) were then generated using a 
vibrating microtome (Leica), and stored in PBS until use.  
 
RNA isolation  
Microdissected hypothalami were homogenised by trituration in 1 ml of TRIzol 
(Invitrogen) before addition of 200 µl of chloroform. Following centrifugation (15 
minutes at 12,000 xg), RNA was precipitated from the aqueous layer by addition of 
500 µl of Isopropanol. Samples were briefly vortexed, allowed to stand for 10 minute 
at RT and then centrifuged (15 minutes at 12,000 xg). The resulting supernatant was 
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carefully removed before adding 1 ml of 75% ethanol diluted in molecular grade 
water (Sigma) and further centrifugation (12 minutes at 5,200 xg). The RNA pellet 
was then briefly air dried, re-suspended in molecular grade water and incubated at 
55 C° for 10 minutes. RNA concentration and quality was determined using a 
spectrophotometer (Nanodrop ND-1000, Thermo Scientific) and samples were 
stored at -80 C° until use.  
 
Primer design and Reverse-Transcriptase PCR 
Gene specific primer pairs (Supplementary Table 1) for use in RT-PCR reactions 
were designed using NCBI primer-BLAST, aiming for regions of least sequence 
conservation between related family members (23), and amplicons that are not only 
small but are also comparable in size across the related family members (Suppl. 
Table 1). To rapidly generate gene-specific templates for in vitro transcription of 
antisense cRNA probes (see below), some reverse primers were additionally tagged 
at their 5’ end with a T7 polymerase-encoding promoter sequence 
(TAATACGACTCACTATAGGG) (23). RT-PCR reactions were carried out in a 
thermocycler (MJ ReseArch) using illustra Ready-To-Go™ RT-PCR beads (GE 
Healthcare Life Sciences) and 1μg of hypothalamic RNA per reaction. For first strand 
synthesis, Oligo (dT)12-18 primers (Invitrogen) and the following cycles were used: 15 
min at 42 °C; 5 min at 95 °C; and 15 min at 6 °C. After addition of 1.5 pmol of 
forward and reverse gene-specific primers, PCR was carried out using: 30 sec at 95 
°C, then 34 cycles of 30 s at 60 °C; 1min at 68 °C; followed by 15 mins at 6 °C. The 
products were resolved alongside 1Kb DNA ladder on 1% w/v agarose gel and 
visualised using ethidium bromide. RT-PCR reactions with β-Actin primers served as 
positive control. 
 
Riboprobe synthesis and In situ hybridization 
Digoxigenin-labelled antisense RNA probes were generated using T7 RNA 
polymerase enzyme (ThermoFisher Scientific) and either T7-tagged RT-PCR 
amplicons (above) or linearized plasmids encoding gene-specific cDNAs 
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(Supplemental Table 2), as templates. Riboprobes were purified using Chroma Spin 
columns (Clontech) and stored at -20 °C until use. 
 
In situ hybridization (ISH) reactions were performed after optimization of published 
protocols (24) as detailed below. Briefly, cryosections were allowed to equilibrate at 
room temperature for 1 hour before a 5 minute fixation in 4% PFA followed by three 
5 min washes with DEPC-PBS. Sections were then treated for 50 mins with 1µg/ml 
proteinase K in a buffer of 50 mM pH 8.0 Tris-HCl, 5 mM EDTA, and post-fixed with 
4% PFA for 5 minutes. After three 5 minute washes with DEPC-PBS, sections were 
incubated for 10min in acetylation solution (1.4% triethanolamine, 0.2% HCl, 0.25% 
acetic anhydride). Prehybridization was carried out for 4 hours in hybridization buffer 
(50% formamide, 5x salt sodium citrate buffer (SSC), pH 7.0, 5x Denhardt’s solution, 
0.25 mg/ml salmon sperm DNA, 0.5 mg/ml yeast tRNA). Hybridization was carried 
out at between 68-72 °C in a hybridization oven for 16-18 hours, using 500 ng/ml of 
riboprobes diluted in hybridization buffer. Post hybridization washes were: 5 mins 
with 5x SSC at RT, followed by three 30 min washes with 0.2x SSC at hybridization 
temperature and a wash with 0.2x SSC at RT. Sections were then washed with Tris-
HCl/saline buffer (100 mM Tris-HCl, pH 7.5, 150 mM NaCl) at RT and blocked in 
Tris-HCl/saline buffer with 10% heat-inactivated Normal Goat Serum (hiNGS) before 
an overnight incubation at 4 °C with alkaline phosphatase-conjugated anti-
digoxigenin conjugated antibodies (Supplementary Table 2) diluted in Tris-HCl/saline 
buffer, containing 3% hiNGS. Excess primary antibody was removed by six 15 min 
washes in Tris-HCl/saline buffer. Colour reaction was carried out in NTM buffer (0.1 
M Tris-HCl, pH 9.5, 0.1 M NaCl, 50 mM MgCl2) containing 2 mM Levamisole, 375 
µg/ml NBT and 187.5 µg/ml BCIP, and allowed to progress at 4 °C until a signal 
became visible. The reactions were stopped by three 5 min washes with PBS, 
followed by a 1-hour wash in 95% ethanol. Sections were then rehydrated for 15 
mins in d.d. H2O before being coverslipped in 50%/PBS glycerol.  
Negative controls included the omission of antisense and/or use of sense cRNA 
probes (Fgf9, Fgf20, Klb, Sef, Spry1, Spry2). Positive controls included probes for 
Neuropeptide Y (Npy), an anorexigenic neurotransmitter expressed by some arcuate 
neurons, which invariably yielded a very strong and specific signal.  
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Immunohistochemistry, immmuno-fluorescent labelling and X-gal staining 
Nonspecific binding sites were blocked by a 2 hour incubation in a solution of 20% 
hiNGS/ 1% Triton X-100 (TX)/PBS, before application of primary antibodies 
(Supplementary Table 2) overnight at 4 °C in 0.2% hiNGS/ 0.1% TX/PBS. Excess 
primary antibodies were removed by five 1 hour washes at RT with a 0.2% hiNGS/ 
0.1% TX solution and this was followed by overnight incubation with the relevant 
secondary fluorophore conjugated antibodies (Supplementary Table 2) diluted in 
0.2% hiNGS/ 0.5% NP-40/ in PBS at 4 °C. The next day, sections were washed six 
times (30 min per wash) before counterstaining with nuclear DNA marker, Hoechst, 
and subsequent mounting in Vectashield (Vector Labs).  
 
For combined ISH and Immunohistochemistry, after completion of the ISH protocol, 
sections were incubated for 1 hour in blocking solution (10% hiNGS/0.3% TX/PBS) 
followed by overnight incubation at 4 °C with mouse anti-GFAP, rabbit anti-GFAP or 
mouse anti-S100β antibodies (Suppl. Table 2) diluted in 0.2% hiNGS/ 0.1% TX/ 
PBS. After three 5 min PBS washes, the DAB staining reaction was performed using 
a DAB peroxidase substrate kit (Vector Labs) according to the manufacturer’s 
instructions. After five 1 min washes with double distilled water, sections were 
preserved by coverslipping with 50% glycerol/PBS solution. 
 
To detect the product of the lacZ-reporter gene, β-galactosidase, brains of Fgf10-
lacZ reporter mice were preserved in Mirsky’s fixative (National Diagnostics) 
overnight at 4 ºC, washed three times with PBT (PBS with 0.1% Tween-20) before 
being incubated with the X-gal substrate solution (2 mM MgCl2, 5 mM 
K4Fe(CN)6.3H2O, 0.02% v/v NP-40, 0.1% v/v X-Gal; diluted in PBS) at 37 ºC for 30 
minutes. Samples were then post fixed with 4% PFA, and dehydrated into absolute 
ethanol for subsequent use and sectioning (see above). 
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Image capture and analysis 
All images were captured using a Zeiss Axioplan 2 microscope and Axiovision 4.8 
software. High magnification of pERK immunostaining was imaged and analysed by 
3D reconstruction of 1 µm optical sections (z stacks), captured using an Apotome 
attachment. Images were post-processed (adjustment of brightness, contrast, levels 
and unsharp mask) using FIJI, Axiovision and Photoshop software packages. 
 
Results 
Global analysis: detection of distinct FGFs and signalling modulators and 
predominance of FGF-receptor IIIc isoforms 
To determine which components of the FGF signalling system need to be mapped 
spatially in the hypothalamus, we first undertook a gross RT-PCR screen of mRNA 
expression derived from 30 to 45 day-old (P30-P45) animals. Industrially pre-
aliquoted substrates (illustra Ready-To-Go beads) were used to amplify comparable 
amplicon sizes. We opted for an RNA-based and gene-reporter analysis (here and 
below) as antibodies to FGFs often detect multiple related family members, and in 
the case of FGFRs, fail to discriminate between isoforms in immunolabellig studies. 
Animals older than P30 were used as the full spectrum of tanycytes subtypes as well 
as the connectivity of hypothalamic neurons is fully established by this age (25). 
FGFRs 1 to 3 exist as alternatively-spliced isoforms termed ‘IIIb’ and ‘IIIc’, depending 
on alternate usage of exons that encode the amino half of the receptors’ third 
extracellular Ig-like domain, whereas FGFR4 possesses only the IIIc form. Use of 
isoform-specific primers showed that FGFRs 1-3 are the predominantly expressed 
receptors, specifically, their IIIc isoforms (Fig. 1A), suggesting that IIIc-activating 
FGF ligands are the likely drivers of canonical FGFR signalling in hypothalamus. 
Use of primer pairs for all 22 mouse Fgfs (Supplementary Table1) detected products 
of the expected size for Fgfs -1, -2, -5, -7, -8, -9, -10, -11, -12, -13, -14, -16, -17, -18, 
20 and 21 (Fig. 1B,B’). Multiple bands were detected for Fgfs -5 and -8, possibly 
representing their closely related isoforms (26). Co-receptor Klotho-β, which is 
required for FGF-19 and -s21 action, as well as FGFR signalling modulators Spry1, 
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Spry2, Spry3 and Mkp3 but not Sef or Spry4, were also detectable, with Sprys -2 
and -3 showing stronger expression (Fig. 1C). Pea3 (also known as Etv4), a 
transcriptional target of FGF signalling was also present.  
This broad screen reveals that various components of the FGF signalling pathway 
are in place to mediate exogenous and to potentially augment endogenous FGF 
signalling in the hypothalamus. 
 
Predominance of Fgf receptors -1 and -2 in β-tanycyte domain 
The gross RT-PCR screen (above) was performed using bulk tissue that contains 
multiple cell compartments – the Median Eminence (M.E.), the ependymal cell wall 
and the hypothalamic parenchyma. To delineate specific expression of FGF 
signalling apparatus in tanycytes and the flanking mediobasal nuclei - Arcuate (Arc), 
ventromedial (VMN), dorsomedial (DMN) and lateral hypothalamus area (LHA) - at 
high resolution, we performed mRNA in situ hybridization on coronal sections 
containing the central part of the M.E. (Bregma -1.45 to -1.94) from P60-P80 mice. 
Because the expression of astroglial marker, GFAP, is normally prominent in the α-
tanycyte domain and dorsal ependymal cells, and absent from β-tanycyte domain (1, 
4)(Suppl. Fig. 1), the in situ hybridization analysis was combined with mouse anti-
GFAP immunolabelling to investigate the selective expression of candidate genes 
within alpha vs beta tanycyte subtypes.  
We found that Fgfr1 and Fgfr2 are expressed predominantly in the GFAP-ve β-
tanycyte domain (Fig. 2A,A’,B). Interestingly, the strongest Fgfr1 signal was 
observed in the floor of the 3V, which harbours the β2 subtype (Fig. 2A’), whilst Fgfr2 
was equally strong in both β2 and β1 tanycyte domains, as well as the transition 
zone between β1 and α-tanycytes (Fig. 2B; (1)). Fgfr1 expression was also detected 
in cells of the Arc, DMN and LHA, with strongest expression in the VMN (Fig. 2A). By 
contrast, Fgfr2 riboprobes only weakly stained cells in the Arc, VMN, DMN and LHA, 
as well as subependymal cells of the M.E. (Fig. 2B and data not shown). 
Interestingly, Fgfr3 expression was absent from the ependymal cell wall altogether, 
instead being abundant in cells scattered uniformly throughout the hypothalamic 
parenchyma, reminiscent of glial cell distribution (Fig. 2C), as well as spare cells in 
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the M.E. We combined Fgfr3 in situ with immunolabelling for glial/ progenitor cell 
marker, S-100β, only to find prevalent co-expression of these markers, confirming 
the glial identity of most Fgfr3-expressing cells (Fig. 2C,C’). Glial expression of Fgfr3 
is precedented in the embryonic mouse spinal cord, where Fgfr3 delineates most 
GFAP+ astrocytes (27). Use of Digoxygenin-labelled Fgfr4 cRNA probes did not 
yield a stain in our in situ hybridization reactions, consistent with a recent qRT-PCR 
profiling of NPY-GFP+ sorted arcuate cells (28). 
 
Expression of FGF signalling modulators, mediators and targets overlaps with 
FGF receptors 
A key feature of FGF signalling is the transcriptional activation of its own 
downstream negative regulators to fine-tune intracellular levels of signalling (9). 
Exploiting this phenomenon, we investigated the domains of Spry family and Mkp3 
expression to ascertain exactly where endogenous FGFR signalling may be 
occurring in the mediobasal hypothalamus. In situ hybridization with Spry1 
riboprobes (Fig. 3A, A’) yielded a strong signal in β-tanycytes and cells of the Arc, 
although expression in VMN, DMN and LHA was also evident. Co-labelling with 
GFAP antibodies revealed a weak expression in the α-tanycyte domain (Fig. 3A’). By 
contrast, use of Spry2 riboprobes (Fig. 3B) showed a more restricted pattern, 
composed of a weak signal in β tanycytes, and scattered expression in the Arc, LHA 
and subependymal M.E. Spry3 ISH reactions produced a weak background signal. 
Mkp3 signal was restricted to scant cells in the LHA/ Tuberal nucleus (Fig. 3C).  
Another transcriptional target of FGF signalling is the transcription factor Etv4 (Pea3) 
[16-19]. To detect the domain of its expression, we double labelled hypothalamic 
sections of an Etv4-GFP reporter mouse, with anti-GFP as well as anti–GFAP 
antibodies, and observed a GFP signal in cells of caudal VMN and LHA (caudal to 
bregma –1.94), but not in tanycytes or GFAP+ parenchymal astrocytes (Fig. 3D,D’).  
MAP Kinase /ERK signaling pathway is a major transducer of FGFR signalling and is 
inhibited by Sprouty proteins (9). To detect focal activation of this pathway, we 
immunolabelled for the phosphorylated form of ERK (pERK) and found a positive 
signal in parenchymal cells (Fig. 3E), particularly in the Arc, DMN and LHA, but not 
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VMN. With respect to the ependymal compartment, however, we noticed a rostro-
caudal difference in pERK stain, with scarce signal in α and β- tanycytes at bregma -
1.70 (Fig. 3E’), contrasting with distinct clusters of pERK-positive β1-tanycytes in 
more caudal sections, at Bregma -2.06 and beyond, until the third ventricle recedes 
(Fig. 3F, F’).  
 
FGF ligands are expressed in tanycytes in two distinct patterns 
The presence of FGFRs (IIIc isoforms) and FGF signalling modulators in the 
hypothalamus is suggestive of a necessity for cognate ligand/s. To delineate the 
cohort of putative ligands involved, we performed in situ hybridization using Fgf-
specific cRNA probes and used transgenic reporter mice. Four FGF candidates and 
two main domains of expression emerged from this screen.  
The expression domain of Fgfs-1 and -9 overlapped in the 3V wall with a restriction 
to the α-tanycyte domain (Fig. 4A’-A’’,B’-B’). Interestingly, ventricular expression of 
Fgf9, as judged by X-gal staining of Fgf9-lacZ brain, was also confined to rostral 
sections and absent from caudal bregma co-ordinate -1.82, onwards. Parenchymal 
staining for these FGFs (Fig. 4A, B; Suppl. Fig. 2A, B) was most intense in the VMN, 
with sporadic staining of cells in the Arc, DMN and LHA. By contrast, expression of 
Fgfs -2 and -18 encompassed β1- as well as α-tanycytes (Fig. 4C,D; Suppl. Fig. 2C). 
Fgf2 expression in the α-tanycyte domain tapered off sharply dorsally, and so is 
therefore likely confined to the more ventral α2-tanycyte subtype, and ventrally, a 
weak patchy pattern of expression was seen in β2 tanycytes. Fgf18 expression was 
determined by activation of the tdTomato-dsred marker upon tamoxifen treatment of 
Fgf18creERT2::Rosa-tdTomato-dsred mice (3-day tamoxifen pulse; 1-day chase; 
n=2). A tight cluster of tdTomato-expressing (Tom+) cells was observed spanning β1 
and ventral α-tanycyte domains, in addition to scarce Tom+ cells in dorsal parts of 
the 3V epithelium, well beyond tanycyte domain (not shown). It is noteworthy that the 
tracing paradigm used here to report Fgf18 expression, would also report 
descendants of Fgf18-expressing cells. Therefore, scarce Tom+ cells in the dorsal 
3V epithelium may reflect dispersion of Fgf18-expressing cells away from a focal 
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source/site of Fgf18 expression, an interpretation that is consistent with Fgf18 in situ 
hybridization data reported by Robins et al. 2013 (5).  
Fgf5 and Fgf17 cRNA probes yielded a clear signal in the hippocampus (Suppl. Fig. 
3) indicative of successful ISH reactions, but none in the hypothalamus. Probes for 
Fgfs -7, -8 and -20 gave a diffuse non-specific signal, not too dissimilar from sense 
probes, and probes for Fgfs -16 and -21 did not produce any staining (not shown).  
 
Restriction of intracellular FGFs to the parenchymal cell compartment 
In situ hybridization with cRNA probes for intracellular FGFs (11 to 14) revealed a 
predominant expression in the hypothalamic parenchyma and subependymal cells in 
the M.E., but a notable absence from tanycytes themselves. Fgf12 expression 
showed the broadest pattern, being present in the DMN, Arc and LHA, most strongly 
in the VMN (Fig. 4E). Fgf13 was restricted to sparse cells in the DMN and Arc and 
rarely in cells of LHA and ventrolateral VMN (Fig. 4F; and data not shown). Fgf14 
was expressed by only a few cells in the most dorsomedial part of the Arcuate (Fig. 
4G). 
 
Discussion  
Extrinsic modulation of FGF signalling in rodents can elicit dramatic changes in 
metabolism, body weight and plasma glucose clearance, with the hypothalamus 
being envisaged as an anchor for these effects. Therapeutic use of FGFs requires a 
better understanding of the foci and mechanisms by which FGFs operate, and, 
whether endogenous hypothalamic FGF signaling normally has a role to play in 
these processes. On face value our results, summarised in Table 1 and Fig. 5, 
identify beta tanycytes as the primary target and FGF-receptors -1 and 2-IIIc 
isoforms as the main mediators of exogenous or endogenous canonical FGF 
signaling within the ependymal wall of the 3V. Moreover FGFR1 and FGFR3 appear 
as key players in hypothalamic parenchyma but with divergent roles. Our study 
predicts that FGFs 1, 2, 9 and 18, sourced mainly from tanycytes and cells of the 
Ventromedial nucleus, are the key FGF ligands in any endogenous effects on 
ependymal and parenchymal cells. Endogenous FGF signaling is evidenced by 
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intricate expression of FGF pathway modulator and mediators, such as Sproutys and 
phosphorylated-ERK. Collectively, our data forms an integrative working model (Fig. 
5) for testing the regulatory role of FGFs in critical hypothalamic functions. 
 
Comparison with previous profiling studies of the FGF signaling pathway in 
hypothalamus 
Several surverys and atlases (29-32) have documented the presence of FGFs/ 
FGFRs in the hypothalamus, but most are either of low resolution, or of embryonic 
stages prior to formation of tanycytes, or are presented in the saggital plane, which 
does not show the full cohort of 3V ependymal cells and tanycyte subtypes. 
Expression of Fgfr1 and Fgfr2 by tanycytes had been noted in coronal sections 
(Allen Brain Atlas), but their precise cellular domain of expression had not been 
assessed. Recent studies show that the 3V epithelium is highly compartmentalized 
(1, 33, 34), and here we took advantage of general GFAP exclusion form the beta 
tanycyte domain to show that Fgfrs-1 and -2 are mostly restricted to this tanycyte 
subtype. Additionally, co-labelling with S100-β enabled us to show that hypothalamic 
Fgfr3 is mostly associated with glial cells. Noteworthy here is the growing importance 
of hypothalamic glial cells in the modulation of energy balance-regulating neural 
circuits, through neuroinflammatory processes or otherwise (35). Much less has 
been known about the domains of FGF signaling modulators and here we highlight 
Sprys -1 and -2 as putative negative regulators of FGF signalling in tanycytes and 
hypothalamic neurons, although SPRYs can also operate downstream of other 
signaling pathways. With respect to FGF ligands, we can not exclude the possibility 
that other endogenous FGFs, such as 7, 8, 16, 20 and 21, for which are detected by 
RT-PCR but not in ISH reactions, are also involved in hypothalamic functions. 
Exogenously-applied FGFs -8 and -17 can certainly improve glucose homoestasis 
via neurons of the arcuate nucleus (28). Variations across species and/or differential 
levels of Fgf expression are also possible, as Fgf5 was detectable by ISH in the rat 
hypothalamus (36) but not in our study, despite the success of our probes in 
detecting Fgf5 in the hippocampus (Suppl. Fig. 3A) in a similar pattern reported by 
Gomez-Pinilla & Cotman (37). The presence of FGF pathway genes that we have 
characterized at celllular resolution, is supported by a recent drop-seq gene profiling 
of cells in the median eminence and the Arcuate nucleus  (34). However, it is 
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possible that with the use of more sensitive methods, such as isotopic in situ 
hybridization or qPCR on cell sorted subpopulations, new and additional members 
may be identified.  
 
Potential modes and significance of FGF/ FGFR function in tanycytes and 
parenchymal nuclei 
Since canonical FGF signaling requires the activation of FGF-receptors, specifically 
their IIIc isoforms in hypothalamus (Fig. 1A), FGFRs become the focus of debate 
when considering FGF function. Activation of FGFRs can yield a multitude of effects, 
typically involving cell proliferation, differentiation, migration or cytoskeletal 
remodelling (7). We showed that FGFRs 1 and 2 are restricted to β-tanycytes, where 
they could regulate cell proliferation and differentation of these newly-identified 
stem/progenitor cells (38). Indeed, some have envisaged changes in postnatal 
hypothalamic neurogliogenesis as a contributory mechanism to body-weight change 
and insulin-independent glucose lowering effects of exogenous FGFs (11, 39). 
Equally, these effects may involve short or long term alterations in barrier properties, 
nutrient sensing, and cargoing or trafficking of metabolic signals and hormones by β-
tanycytes (2, 38, 40). These cells are certainly enriched in the endocytotic pathway 
molecules, such as caveolins (41), which have been shown to control FGF2/FGFR1 
signalling in other cell types and settings (42). Within the 3V epithelium, β-tanycytes 
also uniquely possess primary cilia (33), as well as receptors for VEGFR3 (43), and 
other key regulators of energy homeostasis such as CNTF (44) and Leptin (38). This 
suggests that β-tanycytes may also be responsive to Hedgehog signalling and/or act 
as a hub of cell signalling, or that their biology relies on synergy between multiple 
signalling pathways. Therefore, fine dissection of other signalling pathways in 
tanycytes is warranted.  
Beta 2-tanycytes are radial glial-like cells whose processes span the width of the 
median eminence. Therefore it is possible that FGFRs -1 and -2 operate not only on 
their apical surfaces, exposed to ventricular-derived FGFs, but also on their basal 
surfaces that are in close proximity to the capillary plexus of the outer M.E. where 
capillary fenestrations would readily allow exposure to circulating FGFs. Hints for the 
heterogeneity and paracine response of β-tanycytes to endogenous FGFs comes 
from caudal expression of phospho-ERK in β1 tanycytes, complemented by rostral 
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expression of Fgf9 in α-tanycytes (Fig. 4B). The rosto-caudal complimentarity of 
ligands and receptor is intriguing but highly reminiscent of developmental settings, 
where mesenchymal and epithelial cells express mutually exclusive cohorts of FGF 
ligands and receptors, to ensure paracrine and uni-directional FGF signaling (9). In 
the hypothalamus, FGFs that are secreted into the 3V space may well be distributed 
by beating cilia of 3V ependymal cells (45) to activate distant receptors. This would 
be akin to critical asymmetrical distribution of FGF8 and Nodal by beating cilia during 
establishment of left-right asymmetry in early vertebrate embryos (46). Similarly, 
strong expression of pERK in the Arcuate (Fig. 3E) and Etv4-GFP and Mkp3 in LH 
is, complemented by strong expression of Fgf9 in the neighbouring VMN (Fig. 4B). 
ERK activation could also reflect receptor activation by FGFs -19 and -21 and Leptin 
molecules that have crossed the blood-brain barrier. Others studies have suggested 
that the suprachiasmatic nucleus is the foci of FGF -19/-21 action, since their co-
receptor -klotho is predominantly expressed by this nucleus (32). 
 
The functioning modes of FGF10 and FGFs 12-14 are more engimatic. Within the 
ependymall wall, Fgf10 expression is also restricted to β-tanycytes (4, 47), but its 
target receptor, FgfR2-IIIb isoform (10) is absent from the hypothalamus (Fig. 1A). 
Similarly, FGFs 12-14 do not normally engage FGFRs but are expressed by cells of 
the hypothalamic parenchyma. Increasing evidence, however, shows that FGFs may 
also function non-canonically. For example, by trafficking to the nucleus/nucleolus, 
either alone, or in complex with FGFRs, to induce nuclear cell signaling or to carry 
out gene-regulating functions via chromatin and RNA-binding properties (48-50). 
FGFs -13 and -14, respectively, regulate the stabilization of microtubules (51) and 
proper functioning of voltage-gated sodium and potassium ion channels (52, 53) and 
so these intracellular FGFs could regulate axonal integrity and transport as well 
conductivity within neurons of the arcuate (Fig. 4F,G) and other hypothalamic nuclei. 
 
Lessons from human mutations and transgenic mouse models of FGF 
signaling pathway 
Is the prediction of FGFRs 1-3 IIIc and FGFs -1, -2, -9 and -18 as key endogenous 
canonical FGF signaling partners in mouse hypothalamus, borne out by naturally-
occuring human mutations or experimental transgenic alleles? With minor exceptions 
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
(e.g.  murine Fgf15 vs human Fgf19), human and mouse FGF signaling apparatus is 
highly conserved, both in expression domain and function. Moreover, tanycytes have 
also been identified in the human hypothalamus (54) and human and rodents 
broadly share common mechanisms for the regulation of energy balance. A 
spectrum of dominant acting mutations in human FGFRs 1 and 2 cause rare 
congenital skeletal syndromes, such as Apert and Pfeiffer (55). However, no 
association between these syndromes and predisposition or resistance to diabetes 
and obesity has been reported. By contrast, a significant number of achondroplasia 
patients that carry activating FGFR3 mutations, also manifest atypical obesity (56). 
Difficulties that bar drawing firm conclusions from human patients though include: the 
germline nature of these mutations which would additionally impact peripheral 
organs or indeed multiple brain regions; their rareness, which may preclude 
statistically valid associations with metabolic/ neuroendocrine defects or diet; and 
their varied molecular mode of function, with some mutant receptors operating in a 
FGF ligand-independent manner.  
 
With respect to engineered mouse models, germline deletion of FGFRs -1 and -2, or 
FGFs -9 or -18 (57) causes prenatal or early postnatal lethality, whilst the loss of 
FGFR3 induces abnormal bone growth. FGF1 and FGF2-deficient mice, show no 
overt abnormalities, even as compound mutants. After challenge with high-fat diet, 
however, these mice show hyperglycemia and insulin resistance, likely due to the 
critical regulation of adipose tissue by FGF1 (58). Mice carrying a gain-of-Fgfr1 
function mutation appear normal (59) but those with a gain-of FgfR2 mutation are 
hypoglycemic and show growth retardation and early death (60). Fortunately, a 
plethora of conditional loss and gain of function alleles for these and other 
FGF/FGFR family genes have been developed to circumvent embryonic/neonatal 
lethality. Their use in cell-type specific and stage-dependent gene targeting, as 
exemplified by recent work (28, 61) will prove valuable for unravelling the exact 
role/s of endogenous FGF signaling, alone or in combination with other signalling 
pathways, in tanycyte biology and the regulation of hypothalamic neuronal functions. 
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Figures and Tables 
 
Figure 1. Gross RT-PCR survey of Fibroblast growth factor ligands, receptors, 
signalling modulators and mediators in the postnatal hypothalamus 
RT-PCR products for Fgf-Receptors -1 to -4 (A); Fgfs 1-23 (B,B’);  and FGF 
signalling modulators and mediators (C). Underlined numbers and letters denote lack 
of detection of the relevant genes. Faints bands for Fgfr2-IIIb isoform and Fgf3 are 
non-specific products, whilst all other RT-PCR products match the expected 
amplicon size, predicted by use of primers listed in Suppl. Table 1. Multiple Fgf5 and 
Fgf8 products possibly represent isoforms of these genes.  
 
Figure 2. Domain-restricted expression of Fgf-Receptors within the walls of the 
3V, and the parenchyma of the mediobasal hypothalamus.  
Representative images of in situ hybridization experiments using Fgfr1 (A,A’), Fgfr2 
(B), and Fgfr3 (C,C’) cRNA probes combined with immunohistochemistry for GFAP 
(A, A’) or S100β (C’), and positive control probe, Neuropeptide Y (Npy; D). Fgfr1 and 
Fgfr2 staining in the 3rd ventricle wall is mostly restricted to β-tanycytes (A,A’,B). 
Fgfr2 expression extends into the transition zone (arrow in B) bordering beta (GFAP-
/S100β-) and alpha (GFAP+/S100β+) tanycytes. Fgfr1 is also expressed in 
hypothalamic nuclei, outlined by dashed lines (A). (C) Distribution of Fgfr3 
expressing cells in hypothalamic parenchyma (C), with most co-expressing glial cell 
marker S100β (C’, several examples arrowed). (D) Neuropeptide Y (NpY) in the 
rostral part of the arcuate nucleus. Approximate bregma co-ordinates in bottom right 
corners. Scale bars, 100 μm. 
 
Figure 3. Focal expression of FGF signalling modifiers and mediators. 
Representative images of Spry1 (A, A’), Spry2 (B), Mkp3 (C) in situ hybridization 
reactions and anti-GFP immunolabelling of Etv4-GFP brain sections (D, D’), alone or 
in combination with GFAP (A, A’, B, C, D, E, E’) or pERK (E, E’, F) immunolabelling. 
Spry1 is found in β- and α-tanycyte domains as well as hypothalamic parenchyma 
(A, A’); Spry2 is observed in β-tanycytes and sporadic cells in hypothalamic 
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parenchyma (B). Mkp3 (C; black arrowheads) and Etv4 (D, D’) are both found only in 
an area corresponding to the Tuberal nucleus. pERK staining is strong in DMN and 
Arc nuclei. Although sparse in ependymal layer of 3V anteriorly (E, E’; white arrow), 
foci of pERK signal is evident caudally in β-tanycytes (F,F’ bregma -2.06, arrows). 
Bregma co-ordinates as indicated in right corners; Scale bars, 100 μm.  
 
Figure 4. Distribution of paracrine- and intracrine-acting FGFs in the 
hypothalamus. 
Representative images showing in situ hybridization reactions to detect Fgf1 (A-A’’), 
Fgf2 (C), and Fgfs 12-14 (E-G); X-gal stain to detect Fgf9 in Fgf9-LacZ reporter mice 
(B-B’’); and tomato-dsred immunolabelling to detect Fgf18 in tamoxifen-treated 
Fgf18-creERT2::R26-tomatodsred mice (D,D’). Additional immunolabelling or 
immunohistochemistry for GFAP in a subset of reactions to reveal the approximate 
domains of beta and alpha tanycytes (A’’, B, B'', C, D, D'). Note the similarity in the 
domains of Fgf -1 and -9 expression (A-B’’), with a restriction to α-tanycyte domain in 
the ependymal wall (black arrows in A’ and B”), prominence in the VMN, contrasting 
with the absence of Fgfs -2 and -18 in the parenchymal compartment (C-D’) and 
their prevalence in both alpha and β1 tanycyte domains, with a weak salt and pepper 
Fgf2 expression in β2 domain. Intracellular Fgfs 12-14 also predominate in the 
parenchymal compartment (E-G), with Fgf12 showing a broader domain of 
expression (E). Bregma co-ordinates as indicated in right corners; Scale bars, 100 
μm. 
 
Figure 5. Schematic of key FGF signalling partners and their putative modes of 
FGF function in the mediobasal hypothalamus.  
Schematic coronal cross section of hypothalamus from approximate bregma -1.82. 
Square cobbles – cells lining of the 3V, showing approximate positioning of tanycyte 
subtypes, including a transition zone (Tz) between α and β subtypes, and their radial 
processes (thin dashed lines). Grey pentagonal boxes - capillary plexus in the outer 
zone of the Median Eminence (M.E.), contacted by β-tanycytes. Blue shading 
denotes the domains of FGF-receptor expression within β-tanycytes, hypothalamic 
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
nuclei, scant subependymal cells in the M.E. and in parenchymal glial cells (star-
shaped), as putative targets of FGF action. Navy blue denotes overlap between 
FgfR1 and FgfR2 expression in the floor of the 3V.  Orange and brown represent the 
domains of canonical (FGFs -1, -2, -9 and -18), and non-canonical (FGFs 11-14) 
expression. Paracrine (orange lines) and autocrine (curved orange lines) effects may 
involve FGFs -1, -2, -9 and -18, released by tanycytes into the 3V lumen or supplied 
to parenchymal cells by α-tanycyte terminals, or produced by parenchymal cells 
themselves. Plasma-derived FGFs could potentially activate FGFRs via distal β-
tanycyte processes. FGFs released into lumen of 3V may circulate and have distant 
functions beyond the mediobasal hypothalamus (dashed arrows). FGFs 12, 13 and 
14 would play non-receptor mediated intracrine functions within the cells of the 
parenchymal nuclei, most prominently in VMN and Arc, and some subependymal 
M.E. cells.  
 
Table 1. Distribution of key FGF signalling players within different cellular 
compartments of the mediobasal hypothalamus. Tapered colouring denotes a 
gradient of intensity of staining (darker ends, higher levels). Single star (*), denotes 
scattered cells expressing the gene and double stars (**) denote higher levels of 
expression or tighter clusters of gene-expressing cells.  
 
Supplementary Table 1. Primer pairs used for the RT-PCR screen and to 
generate cDNA templates for riboprobe synthesis. All primers sequences are 5’ 
to 3’; top rows, forward, and bottom rows reverse primers used. Second column 
indicates the expected amplicon size following RT-PCR reactions. Note, a subset of 
the reverse primers were 5’-tagged with T7-RNA polymerase encoding sequences, 
as described in material and methods section. Star (*) denotes use of these RT-PCR 
generated T7-Pol tagged amplicons as templates for riboprobe synthesis.  
 
Supplementary Table 2.  Primary and secondary antibodies used in this study. 
Antibodies used for immunodetection of Digoxygenin-labelled riboprobes in in situ 
hybridization reactions; or for detection of cell type-specific markers (GFAP and 
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S100β), fluorescent reporter markers (GFP, Tomato-dsred) or cell signalling 
molecules (phosphorylated ERK). Host species, dilution and sources indicated in 
columns 2 to 4, respectively.  
 
Supplementary Figure 1. Absence of GFAP-immuno-reactivity from the floor of 
the 3V wall. Immunolabelling of vibratome sections with Rabbit anti-bovine GFAP 
antibodies (Chemicon Int.) shows the absence of GFAP from ependymal cells of 3V 
corresponding to β-tanycyte domains, certainly β2-tanycyes, mirroring a pattern seen 
with the use of Mouse anti-Porcine GFAP antibodies (Merck), shown in Figures 2 
and 4, and referenced in Suppl. Table 2. Arrows point to the ventral limit of GFAP 
signal. Scale bar, 100 μm. 
 
Supplementary Figure 2. Parenchymal distribution and domain-restricted 
ependymal expression of Fgf1, Fgf9 and Fgf2. High (A, B) and Low (C) power 
images showing, complementing images shown in Figure 4 A-C, to better depict the 
parenchymal distribution and domain-restricted ventricular expression (black arrows) 
of Fgf1 (A), Fgf9 (B) and Fgf2 (C), as determined by in situ hybridization (A,C) or 
analysis of a lacZ-reporter (B). Note the absence of Fgf2 from the parenchymal 
nuclei. Scale bars, 100 μm. 
 
Supplementary Figure 3. Positive expression of Fgfs -5, -17 and -11 in the 
hippocampus. Representative images of coronal brain sections subjected to in situ 
hybridization reactions with antisense riboprobes for Fgf5 (A); Fgf17 (B) and Fgf11 
(C).  Note the positive labelling of the granular layer of the dentate gyrus (DG) and 
parts of CA1-CA3 fields. Scale bars, 100 μm. 
 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
References 
1. Goodman T, Hajihosseini MK. Hypothalamic tanycytes-masters and servants 
of metabolic, neuroendocrine, and neurogenic functions. Frontiers in neuroscience. 
2015; 9387. 
 
2. Prevot V, Dehouck B, Sharif A, Ciofi P, Giacobini P, Clasadonte J. The 
Versatile Tanycyte: A Hypothalamic Integrator of Reproduction and Energy 
Metabolism. Endocr Rev. 2018; 39(3): 333-68. 
 
3. Lee DA, Bedont JL, Pak T, Wang H, Song J, Miranda-Angulo A, Takiar V, 
Charubhumi V, Balordi F, Takebayashi H, Aja S, Ford E, Fishell G, Blackshaw S. 
Tanycytes of the hypothalamic median eminence form a diet-responsive neurogenic 
niche. Nat Neurosci. 2012; 15(5): 700-2. 
 
4. Haan N, Goodman T, Najdi-Samiei A, Stratford CM, Rice R, El Agha E, 
Bellusci S, Hajihosseini MK. Fgf10-expressing tanycytes add new neurons to the 
appetite/energy-balance regulating centers of the postnatal and adult hypothalamus. 
J Neurosci. 2013; 336170-80. 
 
5. Robins SC, Stewart I, McNay DE, Taylor V, Giachino C, Goetz M, Ninkovic J, 
Briancon N, Maratos-Flier E, Flier JS, Kokoeva MV, Placzek M. α-Tanycytes of the 
adult hypothalamic third ventricle include distinct populations of FGF-responsive 
neural progenitors. Nat Commun. 2013; 42049. 
 
6. Ornitz DM, Itoh N. The Fibroblast Growth Factor signaling pathway. Wiley 
Interdiscip Rev Dev Biol. 2015; 4(3): 215-66. 
 
7. Brewer JR, Mazot P, Soriano P. Genetic insights into the mechanisms of Fgf 
signaling. Genes Dev. 2016; 30(7): 751-71. 
 
8. Zhang X, Bao L, Yang L, Wu Q, Li S. Roles of intracellular fibroblast growth 
factors in neural development and functions. Science China Life Sciences. 2012; 
55(12): 1038-44. 
 
9. Hajihosseini MK. Fibroblast growth factor signaling in cranial suture 
development and pathogenesis. Front Oral Biol. 2008; 12160-77. 
 
10. Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. 
Receptor specificity of the fibroblast growth factor family. The complete mammalian 
FGF family. The Journal of biological chemistry. 2006; 28115694-700. 
 
11. Gasser E, Moutos CP, Downes M, Evans RM. FGF1 - a new weapon to 
control type 2 diabetes mellitus. Nat Rev Endocrinol. 2017; 13(10): 599-609. 
12. Degirolamo C, Sabba C, Moschetta A. Therapeutic potential of the endocrine 
fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov. 2016; 
15(1): 51-69. 
 
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
13. Xu Y, Tamamaki N, Noda T, Kimura K, Itokazu Y, Matsumoto N, Dezawa M, 
Ide C. Neurogenesis in the ependymal layer of the adult rat 3rd ventricle. 
Experimental neurology. 2005; 192251-64. 
 
14. Oomura Y, Sasaki K, Suzuki K, Muto T, Li AJ, Ogita Z, Hanai K, Tooyama I, 
Kimura H, Yanaihara N. A new brain glucosensor and its physiological significance. 
The American journal of clinical nutrition. 1992; 55278S-82S. 
 
15. Hanai K, Oomura Y, Kai Y, Nishikawa K, Shimizu N, Morita H, Plata-Salaman 
CR. Central action of acidic fibroblast growth factor in feeding regulation. Am J 
Physiol. 1989; 256(1 Pt 2): R217-23. 
 
16. Sasaki K, Oomura Y, Li AJ, Hanai K, Tooyama I, Kimura H, Yanaihara N, Hori 
T. Actions of acidic fibroblast growth factor fragments on food intake in rats. Obes 
Res. 1995; 3 Suppl 5697S-706S. 
 
17. Sun HD, Malabunga M, Tonra JR, DiRenzo R, Carrick FE, Zheng H, Berthoud 
H-R, McGuinness OP, Shen J, Bohlen P, Leibel RL, Kussie P. Monoclonal antibody 
antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and 
weight loss in rodents and monkeys. American journal of physiology Endocrinology 
and metabolism. 2007; 292E964-76. 
 
18. Lelliott CJ, Ahnmark A, Admyre T, Ahlstedt I, Irving L, Keyes F, Patterson L, 
Mumphrey MB, Bjursell M, Gorman T, Bohlooly-Y M, Buchanan A, Harrison P, 
Vaughan T, Berthoud H-R, Lindén D. Monoclonal antibody targeting of fibroblast 
growth factor receptor 1c ameliorates obesity and glucose intolerance via central 
mechanisms. PLoS One. 2014; 9e112109. 
 
19. Samms RJ, Lewis JE, Lory A, Fowler MJ, Cooper S, Warner A, Emmerson P, 
Adams AC, Luckett JC, Perkins AC, Wilson D, Barrett P, Tsintzas K, Ebling FJ. 
Antibody-Mediated Inhibition of the FGFR1c Isoform Induces a Catabolic Lean State 
in Siberian Hamsters. Curr Biol. 2015; 25(22): 2997-3003. 
 
20. Scarlett JM, Rojas JM, Matsen ME, Kaiyala KJ, Stefanovski D, Bergman RN, 
Nguyen HT, Dorfman MD, Lantier L, Wasserman DH, Mirzadeh Z, Unterman TG, 
Morton GJ, Schwartz MW. Central injection of fibroblast growth factor 1 induces 
sustained remission of diabetic hyperglycemia in rodents. Nat Med. 2016; 22800-6. 
 
21. Huh S-H, Warchol ME, Ornitz DM. Cochlear progenitor number is controlled 
through mesenchymal FGF receptor signaling. eLife. 2015; 4e05921. 
 
22. Lamballe F, Genestine M, Caruso N, Arce V, Richelme S, Helmbacher F, 
Maina F. Pool-specific regulation of motor neuron survival by neurotrophic support. J 
Neurosci. 2011; 31(31): 11144-58. 
 
23. Hajihosseini MK, Heath JK. Expression patterns of fibroblast growth factors-
18 and -20 in mouse embryos is suggestive of novel roles in calvarial and limb 
development. Mech Dev. 2002; 11379-83. 
 
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
24. Palop JJ, Roberson ED, Cobos I. Step-by-step in situ hybridization method for 
localizing gene expression changes in the brain. Methods Mol Biol. 2011; 670207-
30. 
 
25. Bouret SG. Development of Hypothalamic Circuits That Control Food Intake 
and Energy Balance. In: nd, Harris RBS, eds. Appetite and Food Intake: Central 
Control. Boca Raton (FL) 2017: 135-54. 
 
26. Hajihosseini MK, Dickson C. A Subset of Fibroblast Growth Factors (Fgfs) 
Promote Survival, but Fgf-8b Specifically Promotes Astroglial Differentiation of Rat 
Cortical Precursor Cells. Molecular and Cellular Neuroscience. 1999; 14468-85. 
 
27. Pringle NP, Yu WP, Howell M, Colvin JS, Ornitz DM, Richardson WD. Fgfr3 
expression by astrocytes and their precursors: evidence that astrocytes and 
oligodendrocytes originate in distinct neuroepithelial domains. Development. 2003; 
130(1): 93-102. 
 
28. Liu S, Marcelin G, Blouet C, Jeong JH, Jo YH, Schwartz GJ, Chua S, Jr. A 
gut-brain axis regulating glucose metabolism mediated by bile acids and competitive 
fibroblast growth factor actions at the hypothalamus. Mol Metab. 2018; 837-50. 
 
29. Yaylaoglu MB, Titmus A, Visel A, Alvarez-Bolado G, Thaller C, Eichele G. 
Comprehensive expression atlas of fibroblast growth factors and their receptors 
generated by a novel robotic in situ hybridization platform. Dev Dyn. 2005; 234371-
86. 
 
30. Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A, Bernard A, Boe AF, 
Boguski MS, Brockway KS, Byrnes EJ, Chen L, Chen L, Chen TM, Chin MC, Chong 
J, Crook BE, Czaplinska A, Dang CN, Datta S, Dee NR, Desaki AL, Desta T, Diep E, 
Dolbeare TA, Donelan MJ, Dong HW, Dougherty JG, Duncan BJ, Ebbert AJ, Eichele 
G, Estin LK, Faber C, Facer BA, Fields R, Fischer SR, Fliss TP, Frensley C, Gates 
SN, Glattfelder KJ, Halverson KR, Hart MR, Hohmann JG, Howell MP, Jeung DP, 
Johnson RA, Karr PT, Kawal R, Kidney JM, Knapik RH, Kuan CL, Lake JH, Laramee 
AR, Larsen KD, Lau C, Lemon TA, Liang AJ, Liu Y, Luong LT, Michaels J, Morgan 
JJ, Morgan RJ, Mortrud MT, Mosqueda NF, Ng LL, Ng R, Orta GJ, Overly CC, Pak 
TH, Parry SE, Pathak SD, Pearson OC, Puchalski RB, Riley ZL, Rockett HR, 
Rowland SA, Royall JJ, Ruiz MJ, Sarno NR, Schaffnit K, Shapovalova NV, Sivisay T, 
Slaughterbeck CR, Smith SC, Smith KA, Smith BI, Sodt AJ, Stewart NN, Stumpf KR, 
Sunkin SM, Sutram M, Tam A, Teemer CD, Thaller C, Thompson CL, Varnam LR, 
Visel A, Whitlock RM, Wohnoutka PE, Wolkey CK, Wong VY, Wood M, Yaylaoglu 
MB, Young RC, Youngstrom BL, Yuan XF, Zhang B, Zwingman TA, Jones AR. 
Genome-wide atlas of gene expression in the adult mouse brain. Nature. 2007; 
445(7124): 168-76. 
 
31. Fon Tacer K, Bookout AL, Ding X, Kurosu H, John GB, Wang L, Goetz R, 
Mohammadi M, Kuro-o M, Mangelsdorf DJ, Kliewer SA. Research resource: 
Comprehensive expression atlas of the fibroblast growth factor system in adult 
mouse. Mol Endocrinol. 2010; 24(10): 2050-64. 
 
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
32. Bookout AL, de Groot MH, Owen BM, Lee S, Gautron L, Lawrence HL, Ding 
X, Elmquist JK, Takahashi JS, Mangelsdorf DJ, Kliewer SA. FGF21 regulates 
metabolism and circadian behavior by acting on the nervous system. Nat Med. 2013; 
19(9): 1147-52. 
 
33. Mirzadeh Z, Kusne Y, Duran-Moreno M, Cabrales E, Gil-Perotin S, Ortiz C, 
Chen B, Garcia-Verdugo JM, Sanai N, Alvarez-Buylla A. Bi- and uniciliated 
ependymal cells define continuous floor-plate-derived tanycytic territories. Nat 
Commun. 2017; 813759. 
 
34. Campbell JN, Macosko EZ, Fenselau H, Pers TH, Lyubetskaya A, Tenen D, 
Goldman M, Verstegen AM, Resch JM, McCarroll SA, Rosen ED, Lowell BB, Tsai 
LT. A molecular census of arcuate hypothalamus and median eminence cell types. 
Nat Neurosci. 2017; 20(3): 484-96. 
 
35. Douglass JD, Dorfman MD, Thaler JP. Glia: silent partners in energy 
homeostasis and obesity pathogenesis. Diabetologia. 2017; 60(2): 226-36. 
36. Li AJ, Ozawa K, Tsuboyama H, Imamura T. Distribution of fibroblast growth 
factor-5 in rat hypothalamus, and its possible role as a regulator of feeding 
behaviour. Eur J Neurosci. 1999; 11(4): 1362-8. 
 
37. Gomez-Pinilla F, Cotman CW. Distribution of fibroblast growth factor 5 mRNA 
in the rat brain: an in situ hybridization study. Brain Res. 1993; 606(1): 79-86. 
 
38. Balland E, Dam J, Langlet F, Caron E, Steculorum S, Messina A, Rasika S, 
Falluel-Morel A, Anouar Y, Dehouck B, Trinquet E, Jockers R, Bouret SG, Prevot V. 
Hypothalamic tanycytes are an ERK-gated conduit for leptin into the brain. Cell 
Metab. 2014; 19(2): 293-301. 
 
39. Seeley RJ, Sandoval DA. Targeting the brain as a cure for type 2 diabetes. 
Nat Med. 2016; 22(7): 709-11. 
 
40. Benford H, Bolborea M, Pollatzek E, Lossow K, Hermans-Borgmeyer I, Liu B, 
Meyerhof W, Kasparov S, Dale N. A sweet taste receptor-dependent mechanism of 
glucosensing in hypothalamic tanycytes. Glia. 2017; 65(5): 773-89. 
 
41. Peruzzo B, Pastor FE, Blazquez JL, Amat P, Rodriguez EM. Polarized 
endocytosis and transcytosis in the hypothalamic tanycytes of the rat. Cell Tissue 
Res. 2004; 317(2): 147-64. 
 
42. Feng L, Liao WX, Luo Q, Zhang HH, Wang W, Zheng J, Chen DB. Caveolin-1 
orchestrates fibroblast growth factor 2 signaling control of angiogenesis in placental 
artery endothelial cell caveolae. J Cell Physiol. 2012; 227(6): 2480-91. 
 
43. Hou Y, Shin Y-J, Han EJ, Choi J-S, Park J-M, Cha J-H, Choi J-Y, Lee M-Y. 
Distribution of vascular endothelial growth factor receptor-3/Flt4 mRNA in adult rat 
central nervous system. Journal of Chemical Neuroanatomy. 2011; 42(1): 56-64. 
 
44. Kokoeva MV, Yin H, Flier JS. Neurogenesis in the hypothalamus of adult 
mice: potential role in energy balance. Science. 2005; 310(5748): 679-83. 
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
 
45. Faubel R, Westendorf C, Bodenschatz E, Eichele G. Cilia-based flow network 
in the brain ventricles. Science. 2016; 353(6295): 176-8. 
 
46. Meyers EN, Martin GR. Differences in left-right axis pathways in mouse and 
chick: functions of FGF8 and SHH. Science. 1999; 285(5426): 403-6. 
 
47. Hajihosseini MK, De Langhe S, Lana-Elola E, Morrison H, Sparshott N, Kelly 
R, Sharpe J, Rice D, Bellusci S. Localization and fate of Fgf10-expressing cells in 
the adult mouse brain implicate Fgf10 in control of neurogenesis. Mol Cell Neurosci. 
2008; 37857-68. 
 
48. Mikolajczak M, Goodman T, Hajihosseini MK. Interrogation of a lacrimo-
auriculo-dento-digital syndrome protein reveals novel modes of fibroblast growth 
factor 10 (FGF10) function. Biochem J. 2016; 473(24): 4593-607. 
49. Stachowiak MK, Birkaya B, Aletta JM, Narla ST, Benson CA, Decker B, 
Stachowiak EK. "Nuclear FGF receptor-1 and CREB binding protein: an integrative 
signaling module". J Cell Physiol. 2015; 230(5): 989-1002. 
 
50. Kostas M, Lampart A, Bober J, Wiedlocha A, Tomala J, Krowarsch D, 
Otlewski J, Zakrzewska M. Translocation of Exogenous FGF1 and FGF2 Protects 
the Cell against Apoptosis Independently of Receptor Activation. J Mol Biol. 2018; 
430(21): 4087-101. 
 
51. Wu QF, Yang L, Li S, Wang Q, Yuan XB, Gao X, Bao L, Zhang X. Fibroblast 
growth factor 13 is a microtubule-stabilizing protein regulating neuronal polarization 
and migration. Cell. 2012; 149(7): 1549-64. 
 
52. Ali SR, Liu Z, Nenov MN, Folorunso O, Singh A, Scala F, Chen H, James TF, 
Alshammari M, Panova-Elektronova NI, White MA, Zhou J, Laezza F. Functional 
Modulation of Voltage-Gated Sodium Channels by a FGF14-Based Peptidomimetic. 
ACS Chem Neurosci. 2018; 9(5): 976-87. 
 
53. Pablo JL, Pitt GS. FGF14 is a regulator of KCNQ2/3 channels. Proc Natl Acad 
Sci U S A. 2017; 114(1): 154-9. 
 
54. Koopman ACM, Taziaux M, Bakker J. Age-related changes in the morphology 
of tanycytes in the human female infundibular nucleus/median eminence. J 
Neuroendocrinol. 2017; 29(5). 
 
55. Ornitz DM, Itoh N. The Fibroblast Growth Factor signaling pathway. Wiley 
Interdiscip Rev Dev Biol. 2015; 4(3): 215-66. 
 
56. Saint-Laurent C, Garcia S, Sarrazy V, Dumas K, Authier F, Sore S, Tran A, 
Gual P, Gennero I, Salles JP, Gouze E. Early postnatal soluble FGFR3 therapy 
prevents the atypical development of obesity in achondroplasia. PLoS One. 2018; 
13(4): e0195876. 
 
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
57. Hung IH, Schoenwolf GC, Lewandoski M, Ornitz DM. A combined series of 
Fgf9 and Fgf18 mutant alleles identifies unique and redundant roles in skeletal 
development. Dev Biol. 2016; 411(1): 72-84. 
 
58. Jonker JW, Suh JM, Atkins AR, Ahmadian M, Li P, Whyte J, He M, Juguilon 
H, Yin YQ, Phillips CT, Yu RT, Olefsky JM, Henry RR, Downes M, Evans RM. A 
PPARgamma-FGF1 axis is required for adaptive adipose remodelling and metabolic 
homeostasis. Nature. 2012; 485(7398): 391-4. 
 
59. Hajihosseini MK, Lalioti MD, Arthaud S, Burgar HR, Brown JM, Twigg SR, 
Wilkie AO, Heath JK. Skeletal development is regulated by fibroblast growth factor 
receptor 1 signalling dynamics. Development. 2004; 131(2): 325-35. 
 
60. Hajihosseini MK, Wilson S, De Moerlooze L, Dickson C. A splicing switch and 
gain-of-function mutation in FgfR2-IIIc hemizygotes causes Apert/Pfeiffer-syndrome-
like phenotypes. Proc Natl Acad Sci U S A. 2001; 98(7): 3855-60. 
 
61. Lan T, Morgan DA, Rahmouni K, Sonoda J, Fu X, Burgess SC, Holland WL, 
Kliewer SA, Mangelsdorf DJ. FGF19, FGF21, and an FGFR1/beta-Klotho-Activating 
Antibody Act on the Nervous System to Regulate Body Weight and Glycemia. Cell 
Metab. 2017; 26(5): 709-18 e3. 
 
  
  
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
 
 
 
  
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
 
  
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
 
  
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
 
  
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
 
  
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
 
